Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
暂无分享,去创建一个
Michael L. Wang | M. Dreyling | A. Goy | G. Hess | S. Rule | B. Kahl | L. Parisi | K. Qi | J. Hernández‐Rivas | R. Auer | S. Deshpande | Lori Parisi